Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of “Buy” by Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned an average rating of “Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $6.60.

Several research firms have recently commented on TSHA. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. BMO Capital Markets began coverage on Taysha Gene Therapies in a research report on Thursday, June 27th. They set an “outperform” rating and a $5.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Chardan Capital restated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 18th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $8.00 price objective (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th.

Insider Activity

In other Taysha Gene Therapies news, major shareholder Paul B. Manning purchased 1,333,333 shares of the stock in a transaction dated Thursday, June 27th. The shares were purchased at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the acquisition, the insider now directly owns 1,333,333 shares in the company, valued at approximately $2,999,999.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth approximately $370,000. Citigroup Inc. bought a new position in Taysha Gene Therapies in the 3rd quarter worth $888,000. Vanguard Group Inc. boosted its holdings in Taysha Gene Therapies by 235.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after buying an additional 3,738,616 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in Taysha Gene Therapies in the 3rd quarter worth $4,740,000. Finally, RA Capital Management L.P. bought a new stake in Taysha Gene Therapies during the third quarter valued at about $58,373,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Down 0.5 %

TSHA opened at $2.15 on Thursday. The business’s fifty day simple moving average is $2.96 and its 200 day simple moving average is $2.43. Taysha Gene Therapies has a 52 week low of $0.61 and a 52 week high of $4.32. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75. The stock has a market cap of $402.09 million, a PE ratio of -4.39 and a beta of 0.42.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $3.41 million during the quarter, compared to analysts’ expectations of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the prior year, the company earned ($0.28) EPS. As a group, research analysts expect that Taysha Gene Therapies will post -0.43 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.